# **Pediatric Rheumatology**



Poster presentation

**Open Access** 

# Analysis of ceiling effect and score distribution of outcome measures in juvenile idiopathic arthritis (JIA)

B Lattanzi\*1, A Consolaro1, L Trail1, I D'Agostino1, S Pederzoli1, R Vitale1, C Malattia1, A Buoncompagni1, A Loy1, C Visconti2, A Martini1 and A Ravelli1

Address: <sup>1</sup>IRCCS G. Gaslini, Genova, Italy and <sup>2</sup>IRCCS Policlinico San Matteo, Pavia, Italy

from 15th Paediatric Rheumatology European Society (PreS) Congress London, UK. 14–17 September 2008

Published: 15 September 2008

Pediatric Rheumatology 2008, 6(Suppl 1):P109 doi:10.1186/1546-0096-6-S1-P109

This abstract is available from: http://www.ped-rheum.com/content/6/S1/P109

© 2008 Lattanzi et al; licensee BioMed Central Ltd.

## **Background**

The ceiling effect and skewness of score distribution (i.e. tendency for scores to cluster at or towards the normal end of the scale) are potential limitations of outcome measures used in JIA.

### **Objective**

To characterize ceiling effect and score distribution of the main JIA outcome measures.

#### Methods

A total of 1818 visits made from 1989 to 2006 were examined. Percentage of patients with score = 0 and score distribution were assessed for physician and parent global assessments, CHAQ, joint counts, and ESR.

#### **Results**

Frequency of ceiling effect for each measure is shown in table 1. Physician global assessment revealed a tendency towards normal distribution, whereas all other measures were skewed towards the normal end of the scale. However, physician global assessment scores tended to cluster at the two ends of the scale (i.e. towards the 0 and 10 scores). In 69.2% of the visits CHAQ score was > 0.5%. In 19.9% of the visits 5 or more active joints were detected.

#### Conclusion

Ceiling effect was greater for ESR, CHAQ and tender and restricted joint counts. In only 1/5 of the visits made in a wide time frame JIA patients receiving routine care in a tertiary center met inclusion criteria (i.e. active joint count  $\geq$  5) for recent clinical trials of second-line or biologic agents.

Table I:

	Physician global	Parent global	Parent pain	CHAQ	No. swollen joints	No. tender joints	No. restricted joints	No. active joints	ESR*
% score = 0	20.2	22.7	26.7	40.8	27.1	36.5	34.2	23.1	51.7

<sup>\*% &</sup>lt; 20 mm/h.

<sup>\*</sup> Corresponding author